Browse medicines

Use listed on the medicine record

LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.

Use listed on the medicine record

Recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1

Use listed on the medicine record

Primary advanced or recurrent endometrial cancer

Use listed on the medicine record

Moderate-to-severe plaque psoriasis

Use listed on the medicine record

Carcinoid syndrome diarrhea

Use listed on the medicine record

Moderate to severe plaque psoriasis

Use listed on the medicine record

Prophylaxis and the treatment of acute gout flares

Use listed on the medicine record

Organ rejection

Use listed on the medicine record

Generalized pustular psoriasis

Use listed on the medicine record

Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration

Use listed on the medicine record

Moderate-to-severe plaque psoriasis in aduts who are candidates for systemic therapy or phototherapy

Use listed on the medicine record

LENMELDY is indicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD). LENMELDY is an autologous hematopoietic stem cell-based gene therapyindicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD).

Use listed on the medicine record

Acute attacks

Use listed on the medicine record

The risk of hospitalization for heart failure

Use listed on the medicine record

Adult and pediatric patients aged one month and older

Use listed on the medicine record

Complications due to vaccinia vaccination ( 1 ), including

Use listed on the medicine record

KRESLADI is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant. This indication is approved under accelerated approval based on increase in neutrophil CD18 and CD11a surface expression [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Recurrent respiratory papillomatosis

Use listed on the medicine record

As a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein

Use listed on the medicine record

DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adult patients. DRAXIMAGE MAA, after radiolabeling with sodium pertechnetate Tc 99m, is a radioactive diagnostic agent indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients.

Use listed on the medicine record

YESCARTA is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. ( 1.1 ) Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Use listed on the medicine record

LANTIDRA is an allogeneic pancreatic islet cellular therapy indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. Use LANTIDRA in conjunction with concomitant immunosuppression.

Use listed on the medicine record

Aromatic L-amino acid decarboxylase (AADC) deficiency

Use listed on the medicine record

KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. ( 1.1 ) Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Use listed on the medicine record

AVLAYAH is indicated for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II, MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. This indication is approved under accelerated approval based on the reduction of cerebrospinal fluid heparan sulfate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02

Use listed on the medicine record

Immune reconstitution

Use listed on the medicine record

Moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy

Use listed on the medicine record

Unresectable or metastatic melanoma

Use listed on the medicine record

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)

Use listed on the medicine record

The preventive treatment of migraine

Use listed on the medicine record

The preventive treatment of migraine

Use listed on the medicine record

WASKYRA ® is indicated for the treatment of pediatric patients aged 6 months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene and for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.

Use listed on the medicine record

And pediatric patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular

Use listed on the medicine record

Infant botulism caused by toxin type A or B

Use listed on the medicine record

Prophylaxis to prevent attacks of hereditary angioedema